School — Medicine Startups

Valo Health Announces the Acquisition of Courier Therapeutics

“We are enthusiastic about Courier’s proprietary cell-targeting technology because we believe it positions Valo to create a new frontier in cancer-immunotherapies,” said David Berry, Valo CEO.

“This acquisition provides Valo with a unique opportunity to expand our proprietary capabilities into protein therapeutics, thereby extending our modalities and our reach while enabling us to potentially pioneer precision immune modulation as a tool against important diseases such as cancer.”

>> Read more.

Print Friendly, PDF & Email

Leave a Reply

Your email address will not be published.